dexamethasone + floxuridine + irinotecan

This is a combination chemotherapy regimen consisting of dexamethasone, floxuridine (FUDR), and irinotecan (CPT-11). Dexamethasone is a synthetic glucocorticoid with anti-inflammatory and immunosuppressant properties. Floxuridine is an antimetabolite that inhibits DNA synthesis by acting as a pyrimidine analog, primarily used in hepatic arterial infusion for liver metastases. Irinotecan is a topoisomerase I inhibitor that prevents DNA replication in cancer cells. This combination has been studied primarily for the treatment of unresectable or resected hepatic metastases from colorectal cancer, often using hepatic arterial infusion (HAI) for floxuridine and dexamethasone alongside systemic administration of irinotecan. The regimen aims to maximize local control within the liver while providing systemic therapy to address micrometastatic disease[1][2][3].